Clik here to view.
BioDelivery on track for mid-year NDA filing
BioDelivery Sciences (NASDAQ:BDSI) is on track to file a new drug application with the FDA this summer for its Bunavail treatment for opioid dependence, one of two Phase 3 candidates in its product...
View ArticleClik here to view.
Titan implanting treatments for opioid dependence
In the continuing struggle to circumvent abuse of drugs to treat opioid dependence and enhance compliance regimes for better outcomes, Titan Pharmaceuticals (OTCBB:TTNP) is leading the race with a...
View ArticleClik here to view.
Enrollment halfway in Titan Pharma Phase 3 OP trial
Titan Pharmaceuticals (OTCBB: TTNP) said that patient enrollment in the Phase 3 study of Probuphine, its investigational subdermal implant for the maintenance treatment of opioid dependence, has...
View ArticleClik here to view.
Roth starts Titan Pharma at buy
Roth Capital Partners has launched coverage of Titan Pharmaceuticals (OTCBB:TTNP) with a “buy” rating and a price target of $1.25. The stock closed at 47 cents on Monday. “The impetus for our buy...
View ArticleClik here to view.
Relmada cleared for PK study with BuTab
Relmada Therapeutics (OTCQB:RLMD) has received a No Objection Letter from Health Canada to conduct the first pharmacokinetic study with novel formulations of oral, enteric-coated buprenorphine (BuTab,...
View ArticleClik here to view.
Relmada begins proof-of-concept trial for BuTab
Relmada Therapeutics (OTCQB:RLMD) has commenced a proof-of-concept pharmacokinetic study with its novel formulations of oral, enteric-coated buprenorphine (BuTab, or REL-1028) being developed for both...
View ArticleClik here to view.
Titan Pharma Phase 3 data validate ProNeura technology
Titan Pharmaceuticals’ (OTCQB:TTNP) positive topline results from a Phase 3 clinical study of Probuphine, its subdermal implant of buprenorphine for the long-term maintenance treatment of opioid...
View ArticleClik here to view.
FDA accepts Probuphine NDA resubmission; Titan prepares for NASDAQ uplisting
The FDA has accepted for review an NDA for Titan Pharmaceuticals’ (OTCQB:TTNP) Probuphine, a six-month subdermal implant containing buprenorphine hydrochloride for the long-term maintenance treatment...
View ArticleClik here to view.
Titan Pharma advancing pipeline in PD, other disorders
Titan Pharmaceuticals (NASDAQ:TTNP), which is awaiting an FDA approval decision for its six-month Probuphine implant to treat opioid dependence, is advancing its ProNeura implant technology against...
View ArticleClik here to view.
Obama to expand MAT in opioid addiction
President Barack Obama has tackled the opioid epidemic this week by telling health care providers across the country that access to medication-assisted treatment (MAT) must be expanded. He released an...
View ArticleClik here to view.
FDA adcom votes in favor of approving Titan’s Probuphine
The Psychopharmacologic Drugs Advisory Committee of the FDA voted 12-to-5 in favor of approving Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine, the first long-acting, subdermal buprenorphine implant...
View ArticleClik here to view.
BioDelivery on track for mid-year NDA filing
BioDelivery Sciences (NASDAQ:BDSI) is on track to file a new drug application with the FDA this summer for its Bunavail treatment for opioid dependence, one of two Phase 3 candidates in its product...
View ArticleClik here to view.
Titan Pharma receives milestone on Probuphine approval
Titan Pharmaceuticals (NASDAQ:TTNP) has received a $15-million milestone payment from development and commercialization partner, Braeburn Pharmaceuticals, following FDA approval of Probuphine, the...
View ArticleClik here to view.
Titan Pharma sensitivity analyses confirm efficacy of Probuphine
Titan Pharmaceuticals (NASDAQ: TTNP) is presenting data today from four post hoc sensitivity analyses of the final Phase 3 trial of Probuphine at a poster session during The College on Problems of Drug...
View ArticleClik here to view.
Braeburn presents Probuphine data at CPDD meeting
Closely-held Braeburn Pharmaceuticals has presented data from the poster of the Phase 3 study of Probuphine, a six-month subdermal buprenorphine implant for the long-term maintenance treatment of...
View ArticleClik here to view.
First patients treated with Titan Pharma’s Probuphine
The first 10 patients received treatment last week with Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine, following FDA approval on May 26. Probuphine was developed using...
View ArticleClik here to view.
Braeburn provides update on training sessions for Probuphine
Healthcare provider training and certification for Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant will take place on July 15-17 in Denver by Titan’s marketing partner, closely-held Braeburn...
View ArticleClik here to view.
Congress passes Comprehensive Addiction and Recovery Act
The United States Senate on Wednesday voted overwhelmingly to pass the Comprehensive Addiction and Recovery Act (CARA). The Senate vote follows a similar near-unanimous vote in the House of...
View ArticleClik here to view.
JAMA article points to effectiveness of Titan’s buprenorphine implant
A randomized clinical trial reported in the current online issue of the Journal of the American Medical Association found that Titan Pharmaceuticals’ (NASDAQ:TTNP) six-month buprenorphine implant,...
View ArticleTitan implanting treatments for opioid dependence
In the continuing struggle to circumvent abuse of drugs to treat opioid dependence and enhance compliance regimes for better outcomes, Titan Pharmaceuticals (OTCBB:TTNP) is leading the race with a...
View Article
